Literature DB >> 22961257

Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.

Zaher K Otrock, Rami A Mahfouz, Zahera Fahed, Fadi S Farhat, Azzam Ziade, Fadi Nasr, Nader Kassem, Miguel R Abboud.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22961257     DOI： 10.1007/s12185-012-1168-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  7 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

Review 2.  Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Authors:  Massimo Breccia; Fabio Efficace; Giuliana Alimena
Journal:  Cancer Lett       Date:  2010-11-12       Impact factor: 8.679

Review 3.  Milestones and monitoring in patients with CML treated with imatinib.

Authors:  Michael W Deininger
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2008

4.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Authors:  Giuseppe Saglio; Dong-Wook Kim; Surapol Issaragrisil; Philipp le Coutre; Gabriel Etienne; Clarisse Lobo; Ricardo Pasquini; Richard E Clark; Andreas Hochhaus; Timothy P Hughes; Neil Gallagher; Albert Hoenekopp; Mei Dong; Ariful Haque; Richard A Larson; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Authors:  Hagop M Kantarjian; Francis J Giles; Kapil N Bhalla; Javier Pinilla-Ibarz; Richard A Larson; Norbert Gattermann; Oliver G Ottmann; Andreas Hochhaus; Jerald P Radich; Giuseppe Saglio; Timothy P Hughes; Giovanni Martinelli; Dong-Wook Kim; Yaping Shou; Neil J Gallagher; Rick Blakesley; Michele Baccarani; Jorge Cortes; Philipp D le Coutre
Journal:  Blood       Date:  2010-11-22       Impact factor: 22.113

6.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

Authors:  Ellen Weisberg; Paul W Manley; Werner Breitenstein; Josef Brüggen; Sandra W Cowan-Jacob; Arghya Ray; Brian Huntly; Doriano Fabbro; Gabriele Fendrich; Elizabeth Hall-Meyers; Andrew L Kung; Jürgen Mestan; George Q Daley; Linda Callahan; Laurie Catley; Cara Cavazza; Mohammad Azam; Azam Mohammed; Donna Neuberg; Renee D Wright; D Gary Gilliland; James D Griffin
Journal:  Cancer Cell       Date:  2005-02       Impact factor: 31.743

7.  Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.

Authors:  Franck E Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Jootar; Bayard L Powell; Carmino De Souza; Ming Zheng; Tomasz Szczudlo; Philipp le Coutre
Journal:  Cancer       Date:  2011-07-05       Impact factor: 6.860
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.